出生后7至14天启动氢化可的松治疗对接受机械通气的极早产儿死亡或支气管肺发育不良的影响:一项随机临床试验
这项双盲安慰剂对照随机试验在荷兰和比利时的19个新生儿重症监护病房纳入胎龄小于30周和/或出生体重小于1250 g、生后7–14天仍依赖呼吸机的早产儿372例,随机接受22天全身氢化可的松(累积剂量72.5 mg/kg,n=182)或安慰剂(n=190)。主要复合结局死亡或支气管肺发育不良在36周矫正胎龄时氢化可的松组128/181(70.7%)vs 安慰剂组140/190(73.7%),校正风险差-3.6%(95%CI -12.7%至5.4%),校正OR 0.87(95%CI 0.54–1.38),P=0.54。29项次要结局中8项有显著差异,包括36周矫正胎龄死亡(15.5% vs 23.7%,风险差-8.2%,95%CI -16.2%至-0.1%,OR 0.59,95%CI 0.35–0.995,P=0.048);支气管肺发育不良无显著差异(55.2% vs 50.0%,P=0.31)。需胰岛素治疗的高血糖是唯一在氢化可的松组更常见的不良反应(18.2% vs 7.9%)。作者结论认为该结果不支持此适应证使用氢化可的松。
要点
- 主要复合结局死亡或BPD在36周矫正胎龄:氢化可的松组70.7%(128/181)vs 安慰剂组73.7%(140/190),校正OR 0.87(95%CI 0.54–1.38),P=0.54,未达统计学显著。
- 36周矫正胎龄死亡:氢化可的松组15.5% vs 安慰剂组23.7%,风险差-8.2%(95%CI -16.2%至-0.1%),OR 0.59(95%CI 0.35–0.995),P=0.048。
- 支气管肺发育不良:氢化可的松组55.2% vs 安慰剂组50.0%,风险差5.2%(95%CI -4.9%至15.2%),OR 1.24(95%CI 0.82–1.86),P=0.31,无显著差异。
- 需胰岛素治疗的高血糖为唯一在氢化可的松组更常见的不良反应:18.2% vs 7.9%。
- 作者结论:极早产儿生后7–14天使用氢化可的松未改善死亡或BPD复合结局,这些发现不支持该适应证使用氢化可的松。
适用人群与场景
- 胎龄小于30周和/或出生体重小于1250 g、生后7–14天仍依赖呼吸机的极早产儿,来自荷兰和比利时19个新生儿重症监护病房。
- 纳入时间为2011年11月15日至2016年12月23日,随访至出院,结束于2017年12月12日。
处置流程与药物剂量
- 氢化可的松组接受22天疗程全身氢化可的松,累积剂量72.5 mg/kg;对照组接受安慰剂。
研究设计与关键结果
- 研究类型:双盲、安慰剂对照随机临床试验,在荷兰和比利时19个新生儿重症监护病房开展,纳入372例极早产儿,随机分为氢化可的松组(n=182)和安慰剂组(n=190),371例完成试验(氢化可的松组1例家长撤回知情同意)。
- 人群特征:平均胎龄26周,55%为男性。
- 主要结局死亡或BPD(36周矫正胎龄):氢化可的松组128/181(70.7%)vs 安慰剂组140/190(73.7%),校正风险差-3.6%(95%CI -12.7%至5.4%),校正OR 0.87(95%CI 0.54–1.38),P=0.54。
- 29项次要结局中8项显示显著差异,包括36周矫正胎龄死亡:氢化可的松组15.5% vs 安慰剂组23.7%,风险差-8.2%(95%CI -16.2%至-0.1%),OR 0.59(95%CI 0.35–0.995),P=0.048。
- 21项次要结局无显著差异,包括BPD:氢化可的松组55.2% vs 安慰剂组50.0%,风险差5.2%(95%CI -4.9%至15.2%),OR 1.24(95%CI 0.82–1.86),P=0.31。
- 不良事件:需胰岛素治疗的高血糖是唯一在氢化可的松组报告更常见的不良反应(氢化可的松组18.2% vs 安慰剂组7.9%)。
证据类型、等级与局限
- 证据类型:双盲、安慰剂对照随机临床试验(RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,极早产儿生后7–14天使用氢化可的松未改善36周矫正胎龄死亡或BPD复合结局,这些发现不支持该适应证使用氢化可的松。
- 需胰岛素治疗的高血糖在氢化可的松组更常见(18.2% vs 7.9%),床旁使用氢化可的松时需监测血糖。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Dexamethasone initiated after the first week of life reduces the rate of death or bronchopulmonary dysplasia (BPD) but may cause long-term adverse effects in very preterm infants. Hydrocortisone is increasingly used as an alternative, but evidence supporting its efficacy and safety is lacking.
OBJECTIVE: To assess the effect of hydrocortisone initiated between 7 and 14 days after birth on death or BPD in very preterm infants.
DESIGN, SETTING, AND PARTICIPANTS: Double-blind, placebo-controlled randomized trial conducted in 19 neonatal intensive care units in the Netherlands and Belgium from November 15, 2011, to December 23, 2016, among preterm infants with a gestational age of less than 30 weeks and/or birth weight of less than 1250 g who were ventilator dependent between 7 and 14 days of life, with follow-up to hospital discharge ending December 12, 2017.
INTERVENTIONS: Infants were randomly assigned to receive a 22-day course of systemic hydrocortisone (cumulative dose, 72.5 mg/kg) (n = 182) or placebo (n = 190).
MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of death or BPD assessed at 36 weeks' postmenstrual age. Twenty-nine secondary outcomes were analyzed up to hospital discharge, including death and BPD at 36 weeks' postmenstrual age.
RESULTS: Among 372 patients randomized (mean gestational age, 26 weeks; 55% male), 371 completed the trial; parents withdrew consent for 1 child treated with hydrocortisone. Death or BPD occurred in 128 of 181 infants (70.7%) randomized to hydrocortisone and in 140 of 190 infants (73.7%) randomized to placebo (adjusted risk difference, -3.6% [95% CI, -12.7% to 5.4%]; adjusted odds ratio, 0.87 [95% CI, 0.54-1.38]; P = .54). Of 29 secondary outcomes, 8 showed significant differences, including death at 36 weeks' postmenstrual age (15.5% with hydrocortisone vs 23.7% with placebo; risk difference, -8.2% [95% CI, -16.2% to -0.1%]; odds ratio, 0.59 [95% CI, 0.35-0.995]; P = .048). Twenty-one outcomes showed nonsignificant differences, including BPD (55.2% with hydrocortisone vs 50.0% with placebo; risk difference, 5.2% [95% CI, -4.9% to 15.2%]; odds ratio, 1.24 [95% CI, 0.82-1.86]; P = .31). Hyperglycemia requiring insulin therapy was the only adverse effect reported more often in the hydrocortisone group (18.2%) than in the placebo group (7.9%).
CONCLUSIONS AND RELEVANCE: Among mechanically ventilated very preterm infants, administration of hydrocortisone between 7 and 14 days after birth, compared with placebo, did not improve the composite outcome of death or BPD at 36 weeks' postmenstrual age. These findings do not support the use of hydrocortisone for this indication.
TRIAL REGISTRATION: Netherlands National Trial Register Identifier: NTR2768.
参考来源
- Onland W, Cools F, Kroon A, et al. Effect of Hydrocortisone Therapy Initiated 7 to 14 Days After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants Receiving Mechanical Ventilation: A Randomized Clinical Trial. JAMA. 2019. PMID: 30694322. doi:10.1001/jama.2018.21443
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。